Péptidos Colombia
ESEN

Tirzepatide in Colombia: identity, regulatory status and presentations

Tirzepatide is a 39-amino-acid linear polypeptide that PubChem, using the ChEBI description, classifies as a dual agonist of the GIP and GLP-1 receptors. In the query of October 11, 2026, Invima's Unique Drug Code (CUM) registry contained six current sanitary registrations for medicines with tirzepatide as active ingredient, all held by the same holder. The reference in this catalog is none of those medicines, is not covered by those registrations and is offered exclusively for research. The article gathers sourced facts on its identity and regulatory status, refers to the product page for presentations and storage, and does not substitute for the buyer's own document review.

What tirzepatide is

According to the description PubChem takes from ChEBI, tirzepatide is a 39-amino-acid linear polypeptide conjugated to a C20 fatty diacid through a linker attached to the lysine at position 20. The same source classifies it as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. That is a structure- and receptor-level description, and this article goes no further than that classification.

PubChem lists "tirzepatida" and "tirzepatidum" among the synonyms of the molecule. In this catalog, Tirzepatide is classified as a synthetic dual agonist of the GLP-1 and GIP receptors and is listed as a reference intended exclusively for research.

Regulatory status in Colombia: sourced facts

Invima publishes the Unique Drug Code (CUM) on datos.gov.co in four datasets: current registrations, expired registrations, registrations in other statuses and registrations undergoing renewal. In the query of October 11, 2026, the current-registrations dataset contained six sanitary registrations with tirzepatide as active ingredient (ATC code A10BX16). September 16, 2026 is the date of the last data update of that whole dataset on datos.gov.co, not of each registration; according to its rows, one of the six registrations was issued on February 25, 2025 and the other five on March 14, 2025. All six have the same holder, Eli Lilly and Company, the status "Vigente" (current) and the modality "Importar y vender" (import and sell). The other three datasets contained no registration with tirzepatide.

Sanitary registrationIssuedExpiry according to the CUM
INVIMA 2025M-0021750February 25, 2025March 11, 2030
INVIMA 2025M-0021776March 14, 2025April 1, 2030
INVIMA 2025M-0021777March 14, 2025April 1, 2030
INVIMA 2025M-0021778March 14, 2025April 1, 2030
INVIMA 2025M-0021779March 14, 2025No valid date in the dataset (it shows 01/01/1900)
INVIMA 2025M-0021780March 14, 2025April 1, 2030

Those registrations cover that holder's medicines and their registered presentations. The Tirzepatide reference in this catalog is none of those products and is not covered by those registrations: it is offered as a reference intended exclusively for research and, according to the site's sanitary notice (/en/legal/sanitary-notice), the catalog references have no Invima sanitary registration for use in humans or animals.

In 2026, Invima issued at least two health alerts, each originating from a complaint, that name products offered as tirzepatide on social media. Alert No. 95-2026, in a PDF dated in Bogotá on April 21, 2026, concerns a product labeled as tirzepatide that was offered for cosmetic use. Alert No. 181-2026, in a PDF dated June 23, 2026, includes a product named "Tirzepatide" together with four others, one of them bearing the name of retatrutide. This list is not meant to be exhaustive.

According to the text of the two alerts, the products named are not covered by any sanitary registration issued by the competent authority, their marketing in Colombia is illegal and they are considered fraudulent; as the rule breached, they cite Decreto 677 de 1995. Alert 95-2026 adds that the active ingredient tirzepatide must be used only under medical prescription and in line with the indications approved in Colombia, because it is a medicine. The alerts advise the general public to refrain from acquiring the products named, and tell establishments to refrain from distributing and marketing them, because marketing them may lead to sanitary safety measures.

The article "What research grade means for a peptide" explains why that label is not a sanitary registration, and "Importing research peptide supplies into Colombia" describes the difference between importing a supply and importing a drug. Retatrutide, which the catalog classifies as a triple agonist, has its own article: "Retatrutide in Colombia: identity, regulatory status and presentations".

Presentations

The catalogued presentations of Tirzepatide and its technical block are on its catalog product page. This article does not repeat them, because they can change.

Storage

The storage conditions declared by the catalog are covered in the article "Storage and transport of research peptides". This article does not repeat them: the current value is the one shown in the technical block of the Tirzepatide product page.

Frequently asked questions

What is tirzepatide?
It is a 39-amino-acid linear polypeptide that PubChem, using the ChEBI description, classifies as a dual agonist of the GIP and GLP-1 receptors. This catalog lists it as Tirzepatide and offers it exclusively for research.
Does tirzepatide have an Invima sanitary registration?
There are registered medicines with tirzepatide: in the query of October 11, 2026, the current-registrations dataset of the Unique Drug Code contained six sanitary registrations with tirzepatide as active ingredient, all held by Eli Lilly and Company. The reference in this catalog is not covered by those registrations and, according to the site's sanitary notice, has no sanitary registration for use in humans or animals.
What do Invima's health alerts say about products with tirzepatide?
Alerts 95-2026 and 181-2026 name products offered as tirzepatide on social media without a sanitary registration; according to their text, marketing them in Colombia is illegal and they are considered fraudulent. Alert 95-2026 adds that the active ingredient must be used only under medical prescription, because it is a medicine.
Where can the presentations be found?
The catalogued presentations of Tirzepatide and its technical block are on its catalog product page.
Does this article teach reconstitution or how to apply the material?
No. This site does not publish reconstitution steps or routes of administration. The reference is offered exclusively for research.

Sources

Related catalog references

Catalogued references from the families this document covers. Each sheet states presentations, current public price, and what batch documentation can be requested.

  • Tirzepatidesynthetic dual agonist of the GLP-1 and GIP receptors · Metabolic research peptides
  • Retatrutidesynthetic triple agonist of the GLP-1, GIP and glucagon receptors · Metabolic research peptides
  • 5-amino-1mqsmall molecule that inhibits the NNMT enzyme · Metabolic research peptides
  • Adipotidepeptidomimetic with a prohibitin-binding domain · Metabolic research peptides
  • AOD9604modified 176-191 fragment of somatropin · Metabolic research peptides

Keep browsing the catalog

Last reviewed: 2026-10-11. This site presents a technical catalog of references intended exclusively for research, technical or laboratory purposes. The published information is not medical advice, a prescription or a diagnosis, and the references are not for human or veterinary use. The availability, import, sale and dispatch of any reference are subject to document validation and to the health, customs and regulatory rules that apply in Colombia and in the destination country.